Omeros Corp. (OMER) Suspends Huntington's Trial of OMS824
Tweet Send to a Friend
Omeros Corp. (NASDAQ: OMER) provided an update on OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor in development for the treatment ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE